Case study of anti-1-amino-3-F-18 fluorocyclobutane-1-carboxylic acid (anti-[F-18] FACBC) to guide prostate cancer radiotherapy target design

Clinical Nuclear Medicine

Volumn 34, Issue 5, 2009, Pages 279-284

  Jani, Ashesh B ^a   Fox, Timothy H ^a   Whitaker, Daisy ^a   Schuster, David M ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Positron emission tomography; Prostate cancer; Radiotherapy

Indexed keywords

ANTI 1 AMINO 3 FLUOROCYCLOBUTANE 1 CARBOXYLIC ACID F 18; CARBOXYLIC ACID DERIVATIVE; CYCLOBUTANE DERIVATIVE; FLUORINE 18; UNCLASSIFIED DRUG; 1 AMINO 3 FLUOROCYCLOBUTANE 1 CARBOXYLIC ACID; 1-AMINO-3-FLUOROCYCLOBUTANE-1-CARBOXYLIC ACID; CARBOXYLIC ACID; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DOSIMETRY; DRUG UPTAKE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; TREATMENT PLANNING; TUMOR VOLUME; BLADDER; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; METHODOLOGY; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; RADIOGRAPHY; RECTUM; SCINTISCANNING; TREATMENT OUTCOME;

CARBOXYLIC ACIDS; CYCLOBUTANES; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; URINARY BLADDER;

EID: 67849106589     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31819e51e3     Document Type: Article

References (28)

1. Frankel S, Smith GD, Donovan J, et al. Screening for prostate cancer. Lancet. 2003;361:1122-1128.
2. Jani AB, Hellman S. Early prostate cancer: clinical decision-making. Lancet. 2003;361:1045-1053.
3. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296:2329-2335.
4. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325-1332.
5. Jani AB. Management strategies for locally advanced prostate cancer. Drugs Aging. 2006;23:119-129.
6. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233-1239.
7. Forman JD, Porter AT. The experience with neutron irradiation in locally advanced adenocarcinoma of the prostate. Semin Urol Oncol. 1997;15:239 -243.
8. Sylvester JE, Grimm PD, Blasko JC, et al. 15-Year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys. 2007;67:57-64.
9. Yue N, Heron DE, Komanduri K, et al. Prescription dose in permanent (131)Cs seed prostate implants. Med Phys. 2005;32:2496-2502.
10. Martinez A, Gonzalez J, Spencer W, et al. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol. 2003;169: 974-979.
11. Jani AB, Roeske JC, Rash C. Intensity-modulated radiation therapy for prostate cancer. Clin Prostate Cancer. 2003;2:98 -105.
12. Jani AB, Blend MJ, Hamilton R, et al. Influence of radioimmunoscintigraphy on postprostatectomy radiotherapy treatment decision making. J Nucl Med. 2004;45:571-578.
13. Jani AB, Spelbring D, Hamilton R, et al. Impact of radioimmunoscintigraphy on definition of clinical target volume for radiotherapy after prostatectomy. J Nucl Med. 2004;45:238-246.
14. Jani AB, Blend MJ, Hamilton R, et al. Radioimmunoscintigraphy for post-prostatectomy radiotherapy: analysis of toxicity and biochemical control. J Nucl Med. 2004;45:1315-1322.
15. Su A, Blend MJ, Spelbring D, et al. Postprostatectomy target-normal structure overlap volume differences using computed tomography and radioimmu-noscintigraphy images for radiotherapy treatment planning. Clin Nucl Med. 2006;31:139-144.
16. Chen L, Price RA, Wang L, et al. MRI-based treatment planning for radiotherapy: dosimetric verification for prostate IMRT. Int J Radiat Oncol Biol Phys. 2004;60:636-647.
17. Landis DM, Schultz D, Cormack R, et al. Acute urinary retention after magnetic resonance image-guided prostate brachytherapy with and without neoadjuvant external beam radiotherapy. Urology. 2005;65:750-754.
18. Payne GS, Leach MO. Applications of magnetic resonance spectroscopy in radiotherapy treatment planning. Br J Radiol. 2006;79:S16-S26.
19. Hricak H, Choyke PL, Eberhardt SC, et al. Imaging prostate cancer: a multidisciplinary perspective. Radiology. 2007;243:28-53.
20. Dimitrakopoulou-Strauss A, Strauss LG. PET imaging of prostate cancer with 11C-acetate. J Nucl Med. 2003;44:556-558.
21. Farsad M, Schiavina R, Castellucci P, et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med. 2005;46:1642-1649.
22. Kwee SA, Wei H, Sesterhenn I, et al. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med. 2006;47:262-269.
23. Larson SM, Morris M, Gunther I, et al. Tumor localization of 16beta-18F- fluoro-5α-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004;45:366-373.
24. Oka S, Hattori R, Kurosaki F, et al. A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J Nucl Med. 2007;48:46-55.
25. Schuster DM, Votaw JR, Nieh PT, et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48:56-63.
26. Fei B, Kemper C, Wilson DL. A comparative study of warping and rigid body registration for the prostate and pelvic MR volumes. Comput Med Imaging Graph. 2003;27:267-281.
27. Lawson J, Schreibmann E, Jani AB, et al. Quantitative evaluation of a cone beam computed tomography (CBCT)-CT deformable image registration method for adaptive radiation therapy. JAppl Clin Med Phys. 2007;8:96-113.
28. Jani AB, Liauw SL, Blend MJ. The role of indium-111 radioimmunoscintig- raphy in post-radical retropubic prostatectomy management of prostate cancer patients. Clin Med Res. 2007;5:123-131.